U.S. Software Stock News

Why Phibro Animal Health is in focus after Russell index removals Phibro Animal Health (PAHC) has come into focus after being removed from several Russell indices, including the Russell 3000E and Microcap benchmarks, a change that directly affects its index fund exposure. These index removals can prompt mechanical buying or selling by funds that track or reference the affected benchmarks, which can influence trading volumes around the event date rather than reflecting any shift in Phibro...

In late June 2026, WillScot Holdings Corporation (NasdaqCM: WSC) was removed from several major Russell growth indices, including the Russell 1000 Growth and Russell Midcap Growth benchmarks. This broad index removal may alter how quantitatively driven and index-tracking investors engage with WillScot, potentially reshaping the company’s shareholder base and liquidity profile. We’ll now examine how WillScot’s removal from multiple Russell growth benchmarks could influence its existing...

How Tradeweb Markets is Framing Its Latest Trading Metrics Tradeweb Markets (TW) recently released production results for June and the second quarter of 2026, giving investors fresh detail on trading activity across its electronic marketplaces and the fees that flow from that volume. In June, the company reported total trading volume of $69.7 trillion, with average daily volume of $3.2 trillion, described as a 29.5% year-over-year increase. For the second quarter, total trading volume reached...

In late June 2026, Westlake Corporation (NYSE: WLK) was removed from the Russell 1000 Defensive Index and the Russell 1000 Value-Defensive Index, marking its exit from two widely followed benchmarks. This change may alter how quantitatively driven and index-linked investors view the stock’s role in diversified, lower-volatility portfolios. We’ll now examine how Westlake’s removal from these Russell 1000 defensive indices could influence its investment narrative and perceived risk...

With global growth forecasts holding up but risks still tilted to the downside, many investors are looking for income that feels more dependable than market mood swings. That is where Dividend Powerhouses come in: companies offering dividend yields above 5% that are covered by current earnings and have a history of stable, growing payouts. In a world of mixed inflation signals, cautious central banks and uneven regional momentum, a focus on cash returns can help keep a portfolio grounded...

Protagonist Therapeutics has already secured FDA approval and a U.S. launch for its psoriasis drug Icotyde, while its polycythemia vera candidate rusfertide is under FDA priority review with an August 2026 action date. This combination of an on-market product and a late-stage asset under priority review is reshaping how investors view Protagonist’s development-to-commercial transition. We’ll now explore how Icotyde’s U.S. launch and the evolving outlook for rusfertide are influencing...

With inflation, interest rate paths and energy markets all in focus, many investors are looking at nuclear energy stocks as a way to gain exposure to reliable power supply and long term infrastructure trends. The Nuclear Energy Stocks screener filters companies involved in uranium production, fuel enrichment and reactor construction or operation, so you can focus on businesses directly linked to this theme. This article walks through why the current macro backdrop keeps nuclear on the radar...

Axogen (AXGN) has been removed from several Russell indexes, including the Russell Microcap Index and Russell 3000E Index. This change can reshape trading patterns as index funds and passive vehicles rebalance their holdings. See our latest analysis for Axogen. Against the backdrop of these index removals, Axogen’s recent trading has been mixed in the very short term but strong over longer periods. The company has a 1-day share price return of 2.04% and a 90-day share price return of 36.48%,...

Home BancShares (HOMB) heads into its July 15, 2026 earnings call with analysts expecting Q2 earnings of $0.61 per share and a recently declared regular quarterly dividend of $0.21 per share. See our latest analysis for Home BancShares. At a share price of $28.63, Home BancShares has seen a 1-month share price return of 4.53%, while the 3-year total shareholder return of 31.77% and 5-year total shareholder return of 41.95% point to steadier longer term compounding. This suggests recent...

Transport driven inflation is back in focus after Namibia’s annual rate reached 4.4% in June 2026, with transport costs alone contributing 1.9 percentage points. For transportation sector stocks, that kind of cost pressure can influence fuel bills, fares, freight rates, and ultimately profit margins. It can also shift how investors think about pricing power and resilience when inflation is concentrated in a single category. This article looks at 3 transportation stocks from the screener that...

Etsy (ETSY) shares are back in focus after the company reported its first sequential increase in active buyers in two years, along with higher spending per buyer and strong growth in app-based sales. See our latest analysis for Etsy. The recent buyer metrics appear to have shifted sentiment around Etsy. The 30 day share price return of 13.03% and 90 day share price return of 47.50% have contributed to a year to date share price return of 35.68%. This indicates strong recent momentum compared...

Why Monster Beverage’s stock split and index adds matter for investors Monster Beverage (MNST) has put itself in focus after announcing a 2-for-1 stock split, to be paid as a 100% stock dividend, alongside multiple additions to Russell value and defensive benchmarks. See our latest analysis for Monster Beverage. Recent price action around Monster Beverage reflects this attention, with the latest share price at $96.55, a 30 day share price return of 7.10% and a 1 year total shareholder return...

On 27 June 2026, Bright Horizons Family Solutions Inc. (NYSE: BFAM) was removed from several Russell growth benchmarks, including the Russell 1000 Growth, Russell Midcap Growth, and Russell 3000 Growth indexes. This broad removal from key Russell growth indexes may affect how index-tracking and benchmark-aware institutional investors view and hold Bright Horizons shares. We will now examine how Bright Horizons’ removal from multiple Russell growth indexes may influence its existing...

Tompkins Financial (TMP) was recently removed from the Russell 2000 Dynamic Index. This event can shift trading flows as index-tracking funds rebalance, prompting investors to reassess how the stock fits within diversified portfolios. See our latest analysis for Tompkins Financial. Against this index removal backdrop, Tompkins Financial’s 1-day share price return of 0.93% sits within a broader pattern of a 2.75% share price gain over 30 days and 9.06% over 90 days, while the 1-year total...

Cintas (CTAS) heads into its July 15 quarterly report with investors watching whether expectations for higher revenue and a year-over-year earnings increase translate into results that shift sentiment around the stock. See our latest analysis for Cintas. At a share price of $177.69, Cintas has eased back in the short term, with the 1 day and 7 day share price returns both down. A 90 day share price return of 1.58% and a 3 year total shareholder return of 47.60% keep the longer term picture...

Index removals put Repligen in focus Repligen (RGEN) has drawn fresh attention after being dropped from multiple Russell growth and small cap benchmarks, a shift that raises questions about how index changes and existing business pressures intersect for the stock. See our latest analysis for Repligen. Repligen’s recent index removals come after a mixed run in the stock, with a 1 month share price return of 10.61% and a 90 day share price return of 19.85%. However, the year to date share price...

Neurocrine Biosciences has initiated a Phase 2 open-label study of CRENESSITY (crinecerfont) in U.S. children aged 3 months to under 4 years with classic congenital adrenal hyperplasia, alongside reaching target enrollment for a similar early-age trial in the EU, aiming to support a supplemental U.S. filing to extend its current indication. This push into very young pediatric patients addresses a group with no approved therapies and could broaden CRENESSITY’s clinical footprint within...

American Water Works Company (AWK) has put a spotlight on long-term infrastructure spending by releasing a Wastewater Solutions white paper and outlining about US$48b in planned capital improvements over the next decade. See our latest analysis for American Water Works Company. Despite the Wastewater Solutions white paper and the roughly US$48b capital plan, American Water Works Company’s recent momentum has been mixed, with a 4.0% 1 month share price gain contrasting with a 6.1% decline in 1...

AI bias, black box models, and new rules like the Illinois AI safety law are pushing responsible AI from a niche concern into a core risk topic for investors. As regulators lean harder on independent audits and compliance checks, attention is shifting toward companies that help monitor, test, and document AI systems for safety and fairness. This article looks at 3 stocks exposed to that regulatory momentum, all drawn from an AI Regulatory Compliance and Audit Service Providers screener, and...

Gentherm recently entered into a Third Amended and Restated Credit Agreement that replaces its prior facility and establishes a secured five-year US$550 million revolving credit line, including sublimits for swing line loans and letters of credit, backed by guarantees and liens on substantial borrower and guarantor assets. This expanded and covenant‑bound credit capacity, combined with planned investor communication at the July 2026 New Ideas Summer Investor Conference, reshapes how Gentherm...

Penny stocks can look exciting but also confusing, especially when headlines are full of mixed signals on inflation, interest rates, energy prices, and global trade. The Financially Fit Penny Stocks screener focuses on companies trading below $5 that also show signs of solid financial health, which can help you filter out some of the weaker options in this high risk corner of the market. In this article, you will see three of the top stocks from that screener and how they fit into a world...

In late June 2026, Spyre Therapeutics, Inc. (NasdaqGS: SYRE) was removed from several Russell indices, including the Russell 2000 Value, 2500 Value, 3000 Value, 3000E Value, and Small Cap Comp Value benchmarks. This broad index exclusion matters because many passive and benchmark-aware investors adjust their holdings around such reconstitutions, potentially altering trading patterns and liquidity for the stock. Next, we will examine how this broad Russell index removal shapes Spyre...

Autodesk (ADSK) is in focus after a reshuffle of its index memberships, as the stock was added to several Russell midcap and defensive indices while being removed from the Russell Top 200 group. See our latest analysis for Autodesk. The index reshuffle lands at a time when Autodesk's share price has been under pressure, with a 30-day share price return down 6.92% and year to date share price return down 27.26%, while the 1-year total shareholder return is down 27.10%. This points to fading...

In late June 2026, BioAge Labs, Inc. (NasdaqGS:BIOA) was added to multiple Russell Growth Benchmark Indexes, including the Russell 2000, Russell 2500, Russell 3000, Russell 3000E, Russell Microcap, and the Russell Small Cap Comp Growth indexes. This broad index inclusion significantly expands BioAge Labs’ visibility among institutional investors and index-tracking funds that follow these Russell Growth benchmarks. Next, we’ll examine how BioAge Labs’ broad Russell Growth index inclusion...